Narrowband (NB) UV-B (311-313 nm) phototherapy was recently reported to be an effective adjunctive treatment for moderate to severe chronic atopic dermatitis (AD) and was found to be more effective than irradiation with broadband UV-A (320-400 nm) or visible light (>400 nm).1 We herein report the findings of our half-side comparison study in patients with AD on the efficacy of NB UV-B vs medium-dose UV-A1 (340-400 nm), a specific form of UV-A phototherapy that in recent years was introduced for the treatment of AD.2